IP Verse

Advanz Pharma competitive analysis

Explore patent oppositions filed by Advanz Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jul 16, 2026

Patent Number	Title	Applicant	Opposition Date
EP4185318	Extended, High Dose Vegf Antagonist Regimens For Treatment Of Angiogenic Eye Disorders	BAYER HEALTHCARE	Jun 1, 2026
EP3329965	Dosing Regimen Of Anti-Alpha4Beta7-Antibodies	MILLENNIUM PHARMACEUTICALS	Dec 18, 2025
EP3744326	Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone Esters	JANSSEN PHARMACEUTICA	Sep 6, 2024
EP2234617	Dosing Regimen Associated With Long Acting Injectable Paliperidone Esters	JANSSEN PHARMACEUTICA	Dec 3, 2021

Discover the latest PTAB cases involving Advanz Pharma, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Advanz Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jul 16, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
ADVANZ PHARMA SERVICES UK	4	-	-	-
JANSSEN PHARMACEUTICA	1	65	-	1
JANSSEN PHARMACEUTICALS	2	20	-	1